Examining Utilization of Value Assessment Frameworks in Payer Decision-Making and more at ISPOR 2019 New Orleans

May 1, 2019

Xcenda's global HEOR experts join more than 4,200 attendees from around the world at ISPOR 2019 in New Orleans. Timely topics such as value assessment frameworks (VAF) and what to expect on VAF in the future will be our focus. Meet us at booth #501 to meet our team and learn how we can help you navigate the changing healthcare landscape.

Optimizing Outcomes for Our Partners

Join us in New Orleans and learn how we can optimize your brand's access.

Contact us

2019 Presentation Highlights

TUESDAY, MAY 21, 2019 | 7:15 AM - 8:15 AM CDT

SYMPOSIUM: Concept to Coverage: Utilization of Value Assessment Frameworks in Payer Decision-making

Moderator: Kristen Migliaccio-Walle, BS, Director, Global HEOR, Xcenda Panelists: Surya Singh, MD, President Singh Healthcare Advisors; Douglas S. Burgoyne, PharmD, FAMCP, Principal at Cooperative Benefits Group and was the General Market Manager & SVP of Product Development at MagellanRx Management; Rena M. Conti, PhD, is an Associate Professor, Department of Markets, Public Policy and Law Questrom School of Business, Boston University

 

In an era where value assessment frameworks (VAFs) are formally being adopted and impacting coverage, pricing and reimbursement decisions, we examine recent high profile cases where specific VAFs are being utilized and discuss their impact on the broader trend toward formal adoption of VAF recommendations in the United States.

This symposium will also review recent payer trends and will provide perspective from payer decision-makers on their own experiences incorporating "value" into coverage determination.

 

Have immediate needs to evaluate how ICER and other VAFs may impact your product portfolio?

Headshot of Kristen Migliaccio-Walle

Concerned about ICER's Unsupported Price Increase Assessment?

Let's talk about how the current value framework landscape can impact your launch.

Schedule 30 minutes with us at ISPOR 2019 in New Orleans

Tame the “Paper Monster” of Systematic Literature Reviews

Introducing MetaMap Pro

Transform your approach to systematic literature reviews with Xcenda’s new digital platform, MetaMap Pro. And benefit from a tool your HEOR teams will actually want to use.

See what we mean when we say MetaMap Pro helps you “tame the paper monster!” 

Contact us for a demo

Podium and Poster Presentations

Podium Presentation | Wednesday, May 22 | 8:30 AM - 9:30 AM

  • It Is All Relative! Impact of the Institute for Clinical and Economic Review (ICER) Budget Impact Threshold on Pricing Considerations
    Authors: Tom Liu; Kristen Migliaccio-Walle; Duncan Brown
Poster Session I | Monday, May 20 | 10:30 AM - 2:00 PM
  • Recent Health Technology Assessment (HTA) Decisions Across the Globe: a Focus on Ovarian Cancer
    Authors: Anuja Kanaskar, PharmD; David Campbell, PharmD, MS; Kim Riggs, MPH; Kimberly Gittings, PharmD; Kellie Meyer, PharmD, MPH

  • Approaches to Pragmatic Methodology in Oncology Retrospective Studies
    Authors: Marlo Blazer, PharmD, BCOP; Aditya Raju, MS; Augustina Ogbonnaya, MPH; Eileen Farrelly, MPH; Vishal Saundankar, 
    Michael Eaddy, PharmD, PhD

Poster Session II | Monday, May 20 | 3:30 PM - 7:00 PM
  • Costs Associated With Initiating Empagliflozin Versus Other Antihyperglycemic Agents in Patients With Type 2 Diabetes and Cardiovascular Disease: a Retrospective Cohort Study
    Author: Aditya Raju, MS; Dana Stafkey-Mailey, PharmD, PhD

  • The Implementation of Competing Risks Using Different Modeling Techniques and Structures: the Effect on Incremental Cost-effectiveness
    Authors: Duygu Bozkaya, MSc, MBA; Ken O’Day, PhD, MPA

  • A Landscape Assessment of Stand-alone Patient-reported Outcome (PRO) Measures Used in Clinical Trials for Rheumatoid Arthritis (RA)
    Authors: Derek Louie; Kimberly Gittings, PharmD; Somali Burgess, PhD

Poster Session III | Tuesday, May 21 | 10:30 AM - 2:00 PM
  • Health Technology Assessment Decisions for Pain Therapies: Results, Rationale, and Trends
    Authors: Kimberly Gittings, PharmD; Kimberly Riggs, MPH; David Campbell, PharmD, MS; Anuja Kanaskar, PharmD; Kellie Meyer, PharmD, MPH

Poster Session IV | Tuesday, May 21 | 3:30 PM - 7:00 PM
  • Budget Impact of Using Cyclosporine Ophthalmic Solution 0.09% for the Treatment of Dry Eye Disease
    Authors: Duncan Brown, PhD; Rashad Carlton, PharmD, MSPH

  • A Landscape Assessment of Patient-Reported Outcome (PRO) and Observer-Reported Outcome (OBSRO) Measures Used in Clinical Trials for Atopic Dermatitis (AD)
    Authors: Cynthiya Ruban, PhD; Linnea Tennant, PharmD, MBA, MS; Somali Burgess, PhD

  • Multivariate Network Meta-Analysis Models that Incorporate Multiple Outcomes Can Produce More Accurate Comparative Effectiveness Estimates than Standard Univariate Models
    Authors: Nick Ballew; Erika Wissinger, PhD; Kimberly Ruiz, EdM

  • Real-World Experience of Peanut-Allergic Adolescents in the United States: Health-Related Concerns and Resource Utilization for Peanut Allergy 
    Authors: Martine Etschmaier, MPH; Ann Cameron, PhD; Amy Duhig, PhD
Poster Session V | Wednesday, May 23 | 8:30 AM - 2:00 PM
  • Pragmatic Artificial Intelligence-Based Reference Screening in Systematic Reviews. Are Two Robots Better Than One?
    Authors: Sarah Cadarette; Kimberly Ruiz, EdM

  • Current Utilization and Perceptions of Value Assessment Frameworks by Pharmacy and Therapeutics Committees in the United States (US)
    Authors: Anuja Kanaskar, PharmD; Linnea Tennant, PharmD, MBA, MS; Kristen Migliaccio-Walle, BS; Chelsey Campbell, PharmD, MBA

  • Evaluation of the Institute for Clinical and Economic Review (ICER) Public Engagement Process: Stakeholder Comment Analysis
    Authors: Anuja Kanaskar, PharmD; Minha Choi; Linnea Tennant, PharmD, MBA, MS; Kristen Migliaccio-Walle, BS; Jennifer Snow, MPH

  • Comparing Payer and Manufacturer Experiences with HCEI and PIE After Passage of the 21st Century Cures Act
    Authors: Bryan Benitez; Amy Duhig, PhD; Jay Jackson, PharmD, MPH

  • Are Medical Directors’ and Pharmacy Directors’ Attitudes Different Towards Proactive HCEI and PIE?
    Authors: Bryan Benitez; Amy Duhig, PhD; Jay Jackson, PharmD, MPH

  • Influencing Factors and Formulary Consequences of Budget Impact Thresholds as Perceived by Payers
    Authors: Dylan Mezzio, PharmD, MS; Ashton Moradi, PharmD; Stewart Kaufman, MBA; Drew Spargo, PharmD; Ken O’Day, PhD, MPA

  • Risk-Benefit Assessment Using the Likelihood Helped or Harmed Ratio: Similarities and Differences with Incremental Cost-Effectiveness Ratios
    Authors: Ken O’Day, PhD, MPA; Kellie Meyer, PharmD, MPH

  • Trends in the Uptake and Impact of the Institute for Clinical and Economic Review (ICER) Value Assessment Framework (VAF) in Coverage Decisions
    Authors: Linnea Tennant, PharmD, MBA, MS; Anuja Kanaskar, PharmD; Kimberly Gittings, PharmD; Kristen Migliaccio-Walle, BS

  • Value-Based Contracting: Do Perspectives Differ by Payer Type?
    Authors: Rebecca Sugarman, MS; Cynthiya Ruban, PhD; Amy Duhig, PhD; Stew Kaufman, MBA; Jay Jackson, PharmD, MPH

25 Years: Driving innovation in value and access.

Celebrate Xcenda’s anniversary and impact on the industry at ISPOR’s Annual International Meeting in New Orleans!

For 25 years, we’ve been there to help you navigate the complexities of the market so you can demonstrate the value of your product, maximize patient access, and enhance your overall brand performance.
Connect with us in New Orleans